Journal of Public Health Policy

, Volume 39, Issue 4, pp 446–453 | Cite as

Seroepidemiology of hepatitis B virus infection in children 12 years after China’s expanded program on immunization in Qamdo, Tibet

  • Yao HuEmail author
  • Ciyang
  • Dunzhuyongzong
  • Awangluosong
  • Zuoqing Yang
  • Aqing
Original Article


Although hepatitis B vaccine (HepB1) was first recommended through China’s Expanded Program on Immunization (EPI) in 1992, Tibet was able to offer universal HepB1 vaccination starting only in early 2004. This cross-sectional study was conducted to assess, 12 years after administration of HepB1, the seroepidemiology of hepatitis B virus (HBV) infection in children in Qamdo, Tibet. Focusing on a population of individuals ≤ 15 years of age living in Tibet, we analyzed serum samples from 261 healthy children for HBV status based on the presence of hepatitis B surface antigen (HBsAg), antibodies against HBV core antigen (anti-HBc), and antibodies against HBsAg (anti-HBs). Of all participants, 87.4% had received HepB1 vaccination. The overall anti-HBs-positive rate was 30.7%, with isolated anti-HBs in 75 participants (28.7%). Of all those studied, 13 (5.0%) were positive for HBsAg and 18 (6.9%) for anti-HBc. Participants who received vaccination in hospital at delivery had a lower prevalence of HBsAg than that of those born at home. By reducing HBV transmission, the EPI in Tibet protected most Tibetans younger than 15 years from becoming HBV carriers.


Hepatitis B virus Hepatitis B surface antigen Seroepidemiology Tibet Vaccination 



Hepatitis B vaccine


Hepatitis B virus


China’s expanded program on immunization


Hepatitis B surface antigen


Antibodies against HBsAg


Hepatitis B e antigen


Antibodies against HBeAg


Antibodies against HBV core antigen


  1. 1.
    Lu FM, Li T, Liu S, et al. Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepat. 2010;17(Suppl 1):4–9.CrossRefGoogle Scholar
  2. 2.
    Cui F, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765.CrossRefGoogle Scholar
  3. 3.
    Lu J, Zhou Y, Lin X, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS ONE. 2009;4(12):e8467.CrossRefGoogle Scholar
  4. 4.
    Zhao SM, Li HC, Lou H, et al. High prevalence of HBV in Tibet, China. Asian Pac J Cancer Prev. 2001;2(4):299–304.Google Scholar
  5. 5.
    Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016;16(1):80–6.CrossRefGoogle Scholar
  6. 6.
    Zhou Y, Wang H, Zheng J, et al. Coverage of and influences on timely administration of hepatitis B vaccine birth dose in remote rural areas of the People’s Republic of China. Am J Trop Med Hyg. 2009;81(5):869–74.CrossRefGoogle Scholar
  7. 7.
    Ministry of Health, China. Implementation protocol for MOH/GAVI hepatitis B vaccine and safety injection cooperation program; 2003.Google Scholar
  8. 8.
    Ministry of Health, China. The report of national EPI review in 2004. Beijing: The People’s Health Publishing House; 2005. p. 10–57.Google Scholar
  9. 9.
    Cui FQ, Wang XJ, Cao L. Progress in hepatitis B prevention through universal infant vaccination—China, 1997–2006. MMWR Morb Mortal Wkly Rep. 2007;56(18):441–5.Google Scholar
  10. 10.
    Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.CrossRefGoogle Scholar
  11. 11.
    WHO. Hepatitis B. fact sheet N°204. Accessed 10 Aug 2016.
  12. 12.
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefGoogle Scholar
  13. 13.
    Chinese Center for Disease Control and Prevention. China news: viral hepatitis special report [in Chinese]. Accessed 6 Aug 2016.
  14. 14.
    Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–108.CrossRefGoogle Scholar
  15. 15.
    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55. Scholar
  16. 16.
    Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health. 2009;12(suppl 3):S89–92.CrossRefGoogle Scholar
  17. 17.
    Ministry of Health, China. 2006–2010 national guidelines for hepatitis B prevention and treatment. (2016). Accessed 10 Aug 2016.
  18. 18.
    He F, Ma YJ, Zhou TY, et al. The serum anti-HBs level among children who received routine hepatitis B vaccination during infancy in Mianyang City, China: a cross-sectional study. Viral Immunol. 2016;29(1):40–8.CrossRefGoogle Scholar
  19. 19.
    Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906–8.CrossRefGoogle Scholar
  20. 20.
    The Ministry of Health Disease Control Bureau, China Center for Disease Control and Prevention. The report of a national seroepidemiological survey of hepatitis B virus infection in the whole population in China, 2006. Beijing: People’s Medical Publishing House; 2011. p. 30–46.Google Scholar
  21. 21.
    Gheorghe L, Csiki IE, Iacob S, et al. The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. Eur J Gastroenterol Hepatol. 2013;25(1):56–64.CrossRefGoogle Scholar
  22. 22.
    Liao XY, Zhou ZZ, Wei FB, et al. Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization. Hum Vaccin Immunother. 2014;10(1):224–31.CrossRefGoogle Scholar

Copyright information

© Springer Nature Limited 2018

Authors and Affiliations

  • Yao Hu
    • 1
    Email author
  • Ciyang
    • 2
  • Dunzhuyongzong
    • 2
  • Awangluosong
    • 2
  • Zuoqing Yang
    • 3
  • Aqing
    • 4
  1. 1.Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical CollegeFudan UniversityShanghaiChina
  2. 2.Department of Laboratory MedicinePeople’s Hospital of Luolong CountyQamdoChina
  3. 3.Center for Disease Control and Prevention of Loulong CountyQamdoChina
  4. 4.Health Bureau of Luolong CountyQamdoChina

Personalised recommendations